<DOC>
	<DOCNO>NCT00089050</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody gemtuzumab ozogamicin locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Cyclosporine may increase effectiveness gemtuzumab ozogamicin make cancer cell sensitive drug . Combining gemtuzumab ozogamicin cyclosporine may kill cancer cell . PURPOSE : This phase II trial study well give gemtuzumab ozogamicin together cyclosporine work treat old patient relapse acute myeloid leukemia .</brief_summary>
	<brief_title>Gemtuzumab Ozogamicin Cyclosporine Treating Older Patients With Relapsed Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine efficacy gemtuzumab ozogamicin cyclosporine , term complete remission rate , old patient relapse acute myeloid leukemia . - Determine toxicity pharmacokinetics regimen patient . Secondary - Correlate clinical response laboratory study drug susceptibility patient treat regimen . OUTLINE : Patients receive cyclosporine IV continuously 72 hour day 1-3 15-17 . Eight hour initiation cyclosporine infusion , patient receive gemtuzumab ozogamicin IV 2 hour day 1 15 . Treatment continue absence disease progression unacceptable toxicity . Patients follow survival . PROJECTED ACCRUAL : A total 25-50 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Morphologically confirm acute myeloid leukemia ( AML ) bone marrow aspirate More 20 % blast morphologic criterion Relapsed disease ≥ 3 month prior complete remission Blasts CD33positive flow cytometry No primary hematologic disorder precede initial presentation AML No document secondary AML relate prior chemotherapy toxin exposure No acute promyelocytic leukemia ( FAB M3 ) Not candidate transplant therapy No active CNS leukemia PATIENT CHARACTERISTICS : Age 60 Performance status Karnofsky 70100 % Life expectancy Not specify Hematopoietic WBC ≤ 30,000/mm^3 ( hydroxyurea allow ) Hepatic Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 1.5 time ULN Renal Creatinine ≤ 1.5 mg/dL Other HIV negative No uncontrolled infection PRIOR CONCURRENT THERAPY : Biologic therapy Not plan hematopoietic stem cell transplantation immediately study therapy Chemotherapy See Disease Characteristics See Hematopoietic Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other More 1 month since prior investigational agent No concurrent anticancer therapy No administration follow 24 hour cyclosporine administration : Diltiazem Verapamil Erythromycin Clarithromycin Metoclopramide Phenytoin Rifampin Phenobarbital Aminoglycosides Amphotericin B Vancomycin Cimetidine Ranitidine Trimethoprim/sulfamethoxazole Ketoconazole Fluconazole Itraconazole Voriconazole Carbamazepine</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult erythroleukemia ( M6a )</keyword>
	<keyword>adult pure erythroid leukemia ( M6b )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute basophilic leukemia</keyword>
	<keyword>adult acute eosinophilic leukemia</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
</DOC>